利拉鲁肽联合二甲双胍对初诊断超重/肥胖2型糖尿病患者体重、脂肪分布和β细胞功能的影响

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (36 KB)
Export: BibTeX | EndNote (RIS)

Abstract

Objective To investigate the influence of Lilarutide combined with Metformin on bodyweight, fat distribution and β cell function in overweight/obese subjects with early type 2 diabetes mellitus (T2DM).Methods A total of 80 newly diagnosed overweight/obese T2DM patients treated in our hospital from June 2018 to June 2019 were selected as the research objects, and they were divided into the study group and the control group by a random number table method, 40 cases in each group.The control group was treated with Metformin, and the study group was treated with Liraglutide on the basis of the control group.The treatment lasted 24 weeks.Changes in bodyweight, body mass index(BMI), fasting blood glucose (FBG), glycosylated hemoglobin A1c (HbA1c), visceral fat area (VFA), subcutaneous fat area (SFA), homeostasis model assessment-β cell (HOMA-β) and homeostasis model assessment-insulin resistance(HOMA-IR) were compared between the two groups before and after treatment.Results After treatment, the bodyweight, BMI, FBG, HbA1c, HOMA-IR, VFA and SFA of the two groups were lower than those before treatment, and HOMA-β of the two groups was higher than that before treatment, with statistically significant differences (P＜0.05).After treatment, the bodyweight, BMI, FBG, HbA1c, HOMA-IR, VFA and SFA of the patients in the study group were lower than those in the control group, and HOMA-β in the study group was higher than that in the control group, with statistically significant differences (P＜0.05).There was no significant difference in the ratio of VFA to SFA (VSR) between the two groups before and after treatment (P＞0.05).Conclusion Liraglutide has good effects on reducing glucose,weight loss, improving fat distribution and β cell function in overweight/obese subjects with early T2DM.

Key words： Liraglutide Type 2 diabetes mellitus Bodyweight Visceral adipose tissue Islet beta cell

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I20/76

[1]	Zheng Y，Ley SH，Hu FB.Global aetiology and epidemiology of type 2 diabetes mellitus and its complications[J].Nat Rev Endocrinol，2018，14（2）：88-98.
[2]	Hansen E，Hajri T，Abumrad NN.Is all fat the same? The role of fat in the pathogenesis of the metabolic syndrome and type 2 diabetes mellitus[J].Surgery，2006，139（6）：711-716.
[3]	Caspard H，Jabbour S，Hammar N，et al.Recent trends in the prevalence of type 2 diabetes and the association with abdominal obesity lead to growing health disparities in the USA：an analysis of the NHANES surveys from 1999 to 2014[J].Diabetes Obes Metab，2018，20（3）：667-671.
[4]	Drucker DJ，Nauck MA.The incretin system：glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J].Lancet，2006，368（9548）：1696-1705.
[5]	Agers H，Jensen LB，Elbrnd B，et al.The pharmacokinetics，pharmacodynamics，safety and tolerability of NN2211，a new long-acting GLP-1 derivative，in healthy men[J].Diabetologia，2002，45（2）：195-202.
[6]	Reijrink M，de Boer SA，Spoor DS，et al.Visceral adipose tissue volume is associated with premature atherosclerosis in early type 2 diabetes mellitus independent of traditional risk factors[J].Atherosclerosis，2019，290：87-93.
[7]	Hermansen K，Mortensen LS.Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus[J].Drug Saf，2007，30（12）：1127-1142.
[8]	Russell-Jones D，Khan R.Insulin-associated weight gain in diabetes-causes，effects and coping strategies[J].Diabetes Obes Metab，2007，9（6）：799-812
[9]	Nauck M，Frid A，Hermansen K，et al.Efficacy and safety comparison of liraglutide，glimepiride，and placebo，all in combination with metformin，in type 2 diabetes：the LEAD（liraglutide effect and action in diabetes）-2 study[J].Diabetes Care，2009，32（1）：84-90.
[10]	Garber A，Henry R，Ratner R，et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes （LEAD-3 Mono）：a randomised，52-week，phase Ⅲ，double-blind，parallel-treatment trial[J].Lancet，2009，373（9662）：473-481.
[11]	Suzuki D，Toyoda M，Kimura M，et al.Effects of liraglutide，a human glucagon-like peptide-1 analogue，on body weight，body fat area and body fat-related markers in patients with type 2 diabetes mellitus[J].Intern Med，2013，52（10）：1029-1034.
[12]	Santilli F，Simeone PG，Guagnano MT，et al.Effects of liraglutide on weight loss，fat distribution，and β-cell function in obese subjects with prediabetes or early type 2 diabetes[J].Diabetes Care，2017，40（11）：1556-1564.
[13]	Bizino MB，Jazet IM，de Heer P，et al.Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes：a pre-specified secondary study on ectopic fat accumulation[J].Diabetologia，2020，63（1）：65-74.
[14]	Lee YS，Park MS，Choung JS，et al.Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes[J].Diabetologia，2012，55（9）：2456-2468.
[15]	Turner RC，Cull CA，Frighi V，et al.Glycemic control with diet，sulfonylurea，metformin，or insulin in patients with type 2 diabetes mellitus：progressive requirement for multiple therapies （UKPDS 49）[J].JAMA，1999，281（21）：2005-2012.
[16]	DeFronzo RA，Abdul-Ghani MA.Preservation of β-cell function：the key to diabetes prevention[J].J Clin Endocrinol Metab，2011，96（8）：2354-2366.
[17]	Leahy JL，Hirsch IB，Peterson KA，et al.Targeting β-cell function early in the course of therapy for type 2 diabetes mellitus[J].J Clin Endocrinol Metab，2010，95（9）：4206-4216.
[18]	Retnakaran R，Kramer CK，Choi H，et al.Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes：the LIBRA trial[J].Diabetes Care，2014，37（12）：3270-3278.